The in vitro activity of PD 127,391, a dihalogenated quinolone, was compared with those of ofloxacin, ciprofloxacin, nalidixic acid, gentamicin, and cefuroxime against 525 recent isolates and well-characterized antimicrobial agent-resistant strains. The MICs of PD 127,391 against 90% of members of the family Enterobacteriaceae, Bacteroides fragiis, Haemophilus influenzae, Neisseria sp., and Streptococcus pneumoniae were '0.12 ,ug/ml. Some 90% of Pseudomonas aeruginosa and staphylococci were susceptible to 0.25 ,ug of PD 127,391 per ml. Against most strains, PD 127,391 was 2-to 8-fold more active than ciprofloxacin, but it was 64-fold more active than ciprofloxacin against B. fragilis. Strains of members of the family Enterobacteriaceae which were resistant to nalidixic acid were less susceptible to all of the quinolones tested, including PD 127,391. The MIC and minimum lethal concentration of PD 127,391 against three strains of Chlamydia trachomatis were each 0.06 ,ug/ml, and the MIC against 90% of 21 strains of Mycobacterium tuberculosis was 1 ,Iglml. PD 127,391 was less active at pH 5, its maximal activity being at pH 7 to 8. The presence of urine at pH 5.9 decreased the bactericidal activity. The protein binding of PD 127,391 was 2 to 7%, and serum had little effect on activity.
with well-characterized P-lactamase producers or which had altered expression of porin proteins, or they were isolated from clinical trials and known to show reduced susceptibility to quinolone antimicrobial agents.
Sources of antibiotics. The antimicrobial agents studied were from the following sources: PD 127,391, Warner Lambert, Portsmouth, England; ofloxacin, Hoechst Laboratories, Uxbridge, England; ciprofloxacin, Bayer AG, Wuppertal, Federal Republic of Germany; cefuroxime, Glaxo Group Research, Greenford, England; and gentamicin, Roussel Laboratories, Uxbridge, England.
Susceptibility testing. The susceptibility of the strains to the compounds was studied by a routine agar plate dilution method. The inocula were prepared as follows. For all strains except streptococci (including Streptococcus pneumoniae), Neisseria spp., Haemophilus influenzae, and an-* Corresponding author. aerobes, the organisms were grown overnight in nutrient broth to yield a viable count of about 109 CFU/ml. Streptococci, H. influenzae, and Neisseria spp. were grown in brain heart infusion broth (Oxoid Ltd., Basingstoke, England) plus 1% supplement C (Difco, East Molesley, England). Bacteroides spp. were grown in Wilkins-Chalgren broth (Oxoid Ltd.) plus 0.25% sodium succinate. Clostridia were grown in Wilkins-Chalgren broth supplemented with 1% Tween 80 (which had previously been shown to enhance growth). The viable counts were comparable in each broth.
The inocula were obtained by transferring 1 ,ul of an undiluted culture or a 1:100 dilution of an overnight culture to the surface of the antibiotic-containing agar with a multipoint inoculating device (Denley-Tech, Billingshurst, England). The final inocula on the plates were therefore 104 and 106 CFU.
The medium used for the agar dilution procedure was Iso-Sensitest agar (pH 7.2; Oxoid), supplemented as follows: 5% horse blood plus 1% supplement C to support growth of streptococci, H. influenzae, and Neisseria spp.; for anaerobes, Wilkins-Chalgren agar was used.
All plates were incubated in air at 37°C for 24 h, except for the following: the anaerobes were grown in an anaerobic cabinet in an atmosphere of 10% hydrogen-10% carbon dioxide-80% nitrogen; the H. influenzae and Neisseria spp. were incubated in air enriched with 6% carbon dioxide. In addition, Staphylococcus aureus was also incubated in air at 30°C with 5% sodium chloride added to the medium. The MIC of the antibiotic was defined as that concentration (in micrograms per milliliter of agar) at which no more than two colonies were detected. In the case of the higher inoculum, a slight haze of growth was ignored.
The effect of human serum and urine on the MIC and MBC of PD 127,391 was studied with eight strains (two each of Klebsiella spp., Escherichia coli, Pseudomonas aeruginosa, and S. aureus) by a method based on that of Pearson et al. (7); the bactericidal endpoint was 99.9% lethality. An overnight broth culture of these organisms was inoculated into 1 ml of Iso-Sensitest broth with 20 and 70% human serum and fresh pooled human urine at pH 5.9, Iso-Sensitest broth at pH 5, 6, 7, and 8, and decreasing concentrations of the antimicrobial agent.
The triplicate in human serum by an ultrafiltration technique with a Centriflo cone (Amicon Corp., Lexington, Mass.) with an exclusion limit of 50,000 daltons. The concentrations of PD 127,391 used were 0.5, 2, and 10 ,ug/ml. The ultrafiltrate (after pH adjustment to precentrifugation values with CO2 gas) was assayed by a microbiological method against standards prepared in phosphate buffer at pH 6.5 (the pH of the ultrafiltrate). The indicator organism was E. coli Sch 12655 (from Squibb Research, Princeton, N.J.), and the medium was Oxoid antibiotic medium no. 1.
Determination of the activities of PD 127,391, ciprofloxacin, and ofloxacin against three freshly isolated strains of Chlamydia trachomatis was done by using a recently developed fluorescent-antibody method (10) . Briefly, McCoy cell cover slip cultures, treated with 5-iodo-2-deoxyuridine, were infected with approximately 1,000 inclusion-forming units of C. trachomatis. The infected monolayers were then exposed to the concentrations of the antimicrobial agents for 48 h and stained with the immunofluorescent Imagen Chlamydia Test (Boots, Nottingham, England). The MIC was defined as the lowest concentration of antimicrobial agent which inhibited all inclusion development. The minimum lethal concentration was the lowest concentration which inhibited inclusion development in cell sheets exposed to antimicrobial agent for 48 h and then reincubated in antibiotic-free media for a further 48 h.
The susceptibilities of 21 strains of M. tuberculosis to PD 127,391, ciprofloxacin, and streptomycin (as control) were determined by raising an initial inoculum in Middlebrook broth (Difco) and diluting this to provide inocula of 104 and 106 CFU, transferred to Middlebrook agar. The plates were incubated at 37°C in 6% CO2 for 6 weeks.
RESULTS
The results from the 515 isolates tested at an inoculum of 104 CFU are shown in Tables 1 and 2. PD 127,391 was remarkably active against all isolates tested. In particular, among members of the Enterobacteriaceae the most resistant strain tested was a clinical isolate of Providencia stuartii (MIC, 1 ,ug/ml), which was resistant to all other agents tested and had been isolated from the urine of a patient treated with ciprofloxacin (MIC, 16 ,ug/ml). The MIC of PD 127,391 for 90% of members of the Enterobacteriaceae was .0.12 p.g/ ml; generalizing, the MICs of PD 127,391 were 2-to 8-fold lower than those of ciprofloxacin and 8-to 32-fold lower than those of ofloxacin. The differences between the agents tended to be more marked in those strains which were less susceptible to the earlier quinolones (see Table 3 ). Also included in Table 3 are four laboratory-selected mutants of E. coli KL-16: gyrA, nalB, naIC, and nalD. As expected, the gyrA and nalB mutants were four-to eightfold less susceptible than the wild type and nalC was somewhat more susceptible. It would be expected that nalD would be less susceptible to PD 127,391 than the parent strain (as seen with ciprofloxacin), but it appeared to be equally susceptible. Those strains of members of the family Enterobacteriaceae which were less susceptible to nalidixic acid (MIC, -128 ,ug/ ml) were less susceptible to PD 127,391, i.e., an alteration in MIC of the latter from 0.004 ,ug/ml to 0.12 to 0.25 ,ug/ml. This was seen for the other quinolones. Strains possessing characterized ,B-lactamases from Richmond and Sykes (8) ,ug/ml, peptococci and Clostridium difficile being less susceptible than Clostridium perfringes and the peptostreptococci. PD 127,391 was the most active quinolone tested against Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus saprophyticus, all strains being inhibited by .0.25 ,ug/ml. Those strains which were methicillin resistant (i.e., MIC of cefuroxime, .4 ,ug/ml) were equally susceptible to the quinolones, as were the methicillin-susceptible strains. The streptococci tested were all susceptible to PD 127,391. For example, Streptococcus pneumoniae strains were all susceptible to 0.12 ,ug of PD 127,391 per ml. Similarly, 4 ,ug of ciprofloxacin or ofloxacin per ml was required to inhibit 90% of enterococci, but only 0.12 ,ug of PD 127,391 per ml was required.
The MICs and MBCs are shown together with the effect of pH, serum, and urine on the activity of PD 127,391 in Table  4 . In general, there was little difference between the MIC and MBC, or, at most, two to four dilutional steps. PD 127,391 was less active at pH 5, and maximal activity was demonstrated at pH 7 to 8.
Urine at pH 5.9 had a marked effect on the MBC but a lesser effect on the MIC. Serum had little effect on either MIC or MBC, which was mirrored in the very low protein binding; averaged results ranged from 2% for 0.5 jig to 7% for 10 ,ug of PD 127,391 per ml.
The activity of PD 127,391 against three strains of C. trachomatis was a MIC and a minimum lethal concentration of 0.06 ,ug/ml each. The MICs and minimum lethal concentrations of both ciprofloxacin and ofloxacin were 1 ,ug/ml each.
The MIC for 90% of the 21 strains of M. tuberculosis tested was 1, 2, and 2 pg of PD 127,391, ciprofloxacin, and streptomycin, respectively, per ml. The MIC of PD 127,391 ranged from 0.12 to 2 ,ug/ml. One strain resistant to streptomycin (MIC, 8 ,ug/ml) was susceptible to PD 127,391 (MIC, 0.5 ,ug/ml).
DISCUSSION
The major difference between PD 127,391 and the other quinolones tested was the enhanced degree of antimicrobial activity of the former. This encompassed genera which, to date, have been considered to be of marginal susceptibility to the other agents. Members of the family Enterobacteriaceae were remarkably susceptible to PD 127,391, the least susceptible strain having a MIC of 1 p.g/ml. Nalidixic acid resistance was associated with a MIC of PD 127,391 approximately two-fold greater than for a nalidixic acidsusceptible strain. It was interesting to note that the susceptibility to the laboratory-selected mutants of E. coli KL-16 (gyrA, nalB, nalC, and nalD) showed that the nalD strain did not exhibit the expected decreased susceptibility to PD 127,391 (4). This locus encoding quinolone resistance is located on the DNA gyrase B subunit (5), and it is possible that PD 127,391 possesses a somewhat different mode of action to other quinolones. This point requires further study.
Earlier quinolones have been considered markedly less active against anaerobic bacteria (11, 12) . PD 127,391, however, displays considerable activity against B. fragilis, Clostridium sp., and the anaerobic cocci; all anaerobic strains tested were inhibited by 0.25 ,ug/ml or less. These data suggest that PD 127,391 might be useful in the therapy of anaerobic sepsis.
There has been considerable debate on the role of quinolones in the therapy of streptococcal disease, in particular, chest infections caused by Streptococcus pneumoniae (2, 13) . PD 127,391 would appear to be active against Streptococcus pneumoniae, enterococci, and streptococci of Lancefield groups A and B. A further point of difference between PD 127,391 and ciprofloxacin, ofloxacin, and the more recent agent fleroxacin (6) is that PD 127,391 has considerable activity against members of the genus Staphylococcus.
Ciprofloxacin has been shown to have activity against C. trachomatis similar in degree to what we have reported here (MIC, 1 ,ug/ml) (10). It is possible that the activity of PD 127,391, being 16-fold greater than that of ciprofloxacin, indicates that the new agent will be more successful than ciprofloxacin in the therapy of chlamydial urethritis (3).
The results we obtained for the activity of ciprofloxacin against M. tuberculosis are generally in agreement with others (9) . That PD 127,391 is twofold more active warrants clinical study.
The enhanced spectrum of PD 127,391 and its activity against strains resistant to earlier quinolones suggest that it may have an important clinical role. The results of toxicological studies and pharmacokinetic analysis in humans are awaited with interest. 
